Resultats de la cerca - Gideon Bollag

Refinar resultats
  1. 1
    Characterization of full-length neurofibromin: tubulin inhibits Ras GAP activity.

    Characterization of full-length neurofibromin: tubulin inhibits Ras GAP activity. per Gideon Bollag, Frank McCormick, R Clark

    Publicat 1993
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    Discovery of a novel Raf kinase inhibitor.

    Discovery of a novel Raf kinase inhibitor. per John F. Lyons, S M Wilhelm, Barbara Hibner, Gideon Bollag

    Publicat 2001
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  3. 3
    A novel serine kinase activated by rac1/CDC42Hs-dependent autophosphorylation is related to PAK65 and STE20.

    A novel serine kinase activated by rac1/CDC42Hs-dependent autophosphorylation is related to PAK65 and STE20. per George A. Martin, Gideon Bollag, Frank McCormick, Arie Abo

    Publicat 1995
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

    RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF per Poulikos I. Poulikakos, Chao Zhang, Gideon Bollag, Kevan M. Shokat, Neal Rosen

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Protein kinase C directly phosphorylates the insulin receptor in vitro and reduces its protein-tyrosine kinase activity.

    Protein kinase C directly phosphorylates the insulin receptor in vitro and reduces its protein-tyrosine kinase activity. per Gideon Bollag, Richard A. Roth, Jacqueline Beaudoin, Daria Mochly‐Rosen, D E Koshland

    Publicat 1986
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Identification of a Novel Guanine Nucleotide Exchange Factor for the Rho GTPase

    Identification of a Novel Guanine Nucleotide Exchange Factor for the Rho GTPase per Matthew J. Hart, Sanju Sharma, Nadia elMasry, Rong-Guo Qiu, Peter C. McCabe, Paul Polakis, Gideon Bollag

    Publicat 1996
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition

    Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition per Stephen Mok, Jennifer Tsoi, Richard C. Koya, Siwen Hu‐Lieskovan, Brian L. West, Gideon Bollag, Thomas G. Graeber, Antoni Ribas

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    Biochemical and Functional Characterization of Germ Line <i>KRAS</i> Mutations

    Biochemical and Functional Characterization of Germ Line <i>KRAS</i> Mutations per Suzanne Schubbert, Gideon Bollag, Natalya Lyubynska, Hoa Nguyen, Christian P. Kratz, Martin Zenker, Charlotte M. Niemeyer, Anders Molven, Kevin Shannon

    Publicat 2007
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors in<i>BRAF</i>Mutant Thyroid Carcinoma Cells

    Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors in<i>BRAF</i>Mutant Thyroid Carcinoma Cells per Paolo Salerno, Valentina De Falco, Anna Tamburrino, Tito Claudio Nappi, Giancarlo Vecchio, Rebecca E. Schweppe, Gideon Bollag, Massimo Santoro, Giuliana Salvatore

    Publicat 2009
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT–dependent apoptosis in diffuse large B-cell lymphoma

    The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT–dependent apoptosis in diffuse large B-cell lymphoma per Peter G. Smith, Fengfei Wang, Kathryn Wilkinson, Kerry J. Savage, Ulf Klein, Donna Neuberg, Gideon Bollag, Margaret A. Shipp, Ricardo C.T. Aguiar

    Publicat 2004
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer

    CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer per Jingying Xu, Jemima Escamilla, Stephen Mok, John David, Saul J. Priceman, Brian L. West, Gideon Bollag, William H. McBride, Lily Wu

    Publicat 2013
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice

    Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice per Cédric Louvet, Gregory L. Szot, Jiena Lang, Michael R. F. Lee, Nicolas Martinier, Gideon Bollag, Shirley Zhu, Arthur J. Weiss, Jeffrey A. Bluestone

    Publicat 2008
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy

    Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy per Stephen Mok, Richard C. Koya, Christopher Tsui, Jingying Xu, Lídia Robert, Lily Wu, Thomas G. Graeber, Brian L. West, Gideon Bollag, Antoni Ribas

    Publicat 2013
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase <i>BRAF</i> -mutant lung cancer

    Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase <i>BRAF</i> -mutant lung cancer per Ross A. Okimoto, Luping Lin, Victor Olivas, Elton Chan, Evan Markegard, Andrey Rymar, Dana S. Neel, Xiaohong Chen, Golzar Hemmati, Gideon Bollag, Trever G. Bivona

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Targeting BRAFV600E with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer

    Targeting BRAFV600E with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer per Carmelo Nucera, Matthew A. Nehs, Sushruta S. Nagarkatti, Peter M. Sadow, Michal Mekel, Andrew H. Fischer, Paul Lin, Gideon Bollag, Jack Lawler, Richard A. Hodin, Sareh Parangi

    Publicat 2011
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    PLX4032, a potent inhibitor of the B‐Raf V600E oncogene, selectively inhibits V600E‐positive melanomas

    PLX4032, a potent inhibitor of the B‐Raf V600E oncogene, selectively inhibits V600E‐positive melanomas per John Tayu Lee, Ling Li, Patricia Brafford, Marcia van den Eijnden, Molly B. Halloran, Katrin Sproesser, Nikolas K. Haass, Keiran S.M. Smalley, James Tsai, Gideon Bollag, Meenhard Herlyn

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

    Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer per Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, William D. Bradley, Richard J. Lee, Kathleen Schostack, Mary Ellen Simcox, Scott Kopetz, David Heimbrook, Brian Lestini, Gideon Bollag, Fei Su

    Publicat 2011
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma

    Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma per William D. Tap, Ke-Wei Gong, Judy Daring, Yiou Tseng, Charles Ginther, Giovanni M. Pauletti, John A. Glaspy, Richard Essner, Gideon Bollag, Peter Hirth, Chao Zhang, Dennis J. Slamon

    Publicat 2010
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model

    BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model per Daniele Perna, Florian A. Karreth, Alistair G. Rust, Pedro A. Pérez–Mancera, Mamunur Rashid, Francesco Iorio, Constantine Alifrangis, Mark J. Arends, Marcus Bosenberg, Gideon Bollag, David A. Tuveson, David J. Adams

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition

    Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition per Carlos E. Prada, Edwin Jousma, Tilat A. Rizvi, Jianqiang Wu, R. Scott Dunn, Debra A. Mayes, José A. Cancelas, Eva Dombi, Mi‐Ok Kim, Brian L. West, Gideon Bollag, Nancy Ratner

    Publicat 2012
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: